Wanbury (WANBURY)

Turnaround

FairStock Score: 60/100 — STEADY

Score breakdown: P/E: 2/3 · ROCE: 2/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Current Price₹261.35
Market Cap₹913.14 Cr
P/E Ratio13.46
ROCE33.93%
ROE166.95%
Dividend Yield0%
Profit Growth1,000%
Debt/Equity
Sales Growth-19.2%
Promoter Holding43.07%
52-Week Range₹161.5 — ₹358.85
SectorPharmaceuticals & Biotechnology
Book Value₹48.32

Strengths

Concerns

AI Analysis

At first glance, Wanbury looks tempting: price-to-earnings of 14.35 with sales growing 21.73%. But Graham taught me to look beyond the income statement to the balance sheet, and this one is thin. A book value of only ₹10.93 against a market price of ₹261.72 means the price-to-book ratio is 23.95. There is very little asset cushion if the business stumbles. The ROE of 166.95% and ROCE of 33.93% sound spectacular, but a high return on a tiny equity base can evaporate quickly. Profit growth of 1000% is even less reliable; it usually means last year's base was depressed. I would not equate that with durable compounding. The latest quarter revenues of ₹162 Cr and net profit of ₹16 Cr, when annualized, roughly justify the P/E, so the market is not pricing in much growth beyond today. A zero dividend yield means I must depend entirely on price appreciation, and with promoter holding at 43.07%, minority shareholders need to watch governance and cash flow carefully. The Piotroski F-score of 7/9 is reassuring, but I cannot excuse the missing debt/equity figure; without leverage details, I cannot assess financial risk. If the company's recent profit jump is due to a genuine turnaround and it can keep revenue growing at over 20% while converting to cash, then ₹261 may be a reasonable price. But Graham's margin of safety is weak when book value is ₹10.93. I want to see several quarters of consistent earnings before I call this an investment. For now, it is a recovery story with an attractive headline P/E and a fragile balance sheet. I would only monitor it, not buy it.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer